bg-country-switch

We take your feedback seriously

9/21/2020

We take your feedback seriously

At HARTMANN UKI our aim is to continuously improve our offering and make the lives of nurses, doctors and patients that little bit easier. Our products are constantly tested and modified, following feedback from tissue viability nurses, podiatrists and many other specialists. Many of them are happy for this feedback to be shared, so that we can all learn and improve together, offering the very best care and medical products on the market.

It is widely accepted that stress and anxiety can be linked to increased wound-related pain and dressing change.[1] To minimise this stress and to maximise healing, we developed our Atrauman® family of wound contact layers[3,4].

There are three products in the family – Atrauman®, Atrauman® Silicone (when you need an extra level of care) and Atrauman® Ag (when you need to reduce bioburden[8]).

The most widely chosen wound contact layer in the UK[2], Atrauman® can be used on a variety of acute and chronic wound types, such as minor burns and scalds, skin tears and incisions, abrasions, ulcers, exuding and infected wounds. Tracey Jones, a Tissue Viability Nurse comments, “Atrauman® is our 1st choice non-adherent dressing option. It is a high quality, truly non-adherent wound contact layer which we use on a variety of wounds at different times along the healing continuum. The varied size range available also ensures that dressing changes can be simpler and less wasteful.“

As part of our customer journey and continuous improvement we conducted a clinical study of 624 patients using Atrauman® Ag, two-thirds of which had infected wounds. The product was rated 96.7% for ease of removal, 94.8% for tolerability and 94.5% on overall impression[7]. Alison Schofield Tissue Viability Nurse commented, “This is a great product of choice due to the non-adherent contact layer and added silver to perform two roles in one.”[10]

And last but certainly not least, the Atrauman® Silicone range is used for treating delicate and sensitive skin or more complex wounds[12]. It offers a cost saving of 20% against its main competitors*. Kimberley Wilde, Advanced Podiatrist found that it is “an excellent dressing choice for protection of granulation tissue and easy and pain free removal. It is excellent for use in patients who have fragile skin and I have used it successfully in patients with diabetes and peripheral vascular disease.”[10]

Emma Deakin of HARTMANN UKI comments, “We are very proud to have won awards for innovation and customer service at HARTMANN and are thoroughly committed to setting industry standards and investing in new technology. “

Atrauman® has been developed to both improve the patient’s experience and reduce NHS spend, so feedback from healthcare specialists is vital. They are on the front line, trying to offer the very best level of service possible and we want to make sure they are always equipped with the right product for the task in hand, supporting them with the best customer experience in Healthcare.”

To learn more about Atrauman® Family, HARTMANN’s contact layer range click here.

[1] Upton D (2014). Psychological aspect of wound care: implications for clinical practice. J Wound Care 28(2). [2] IMS data on file, May 2020. [3] Data on file: Design Verification Report_Ointment Dressings_15012019. [4] Stephen-Haynes J (2009). The use of Atrauman non-adherent wound dressing in tissue viability. Br J Community Nurs. 14(3): $29· 30, $32-4. [5] Simka M (2005). [Time - Modern strategy of chronic wound management]. Time - Nowoczesna strategia leczenia ran rzewleklych.Polski przeglad chirurgiczny. 77: p. 748-760. [6] Thompson GL (2005). Case Study Atrauman: A descriptive evaluation by historical review and by one specific case history. Hartmann Ag WundForum. [7] H. kapp (2005). Clinical observation study in 624 patients confirms good efficacy and tolerability. Aktuelle Dermatologie. 31: 561– 565. [8] Ziegler. K et al. (2006) Reduced cellular toxicity of a new silver-containing antimicrobial dressing and clinical performance in non-healing wounds. Skin harmacol Physiol. 19.[9] Gray. D (2010). Reduced cellular toxicity and clinical performance of Atrauman Ag. Wounds UK. 6 (4). [10] Data on file, June 2020. [11] LeBlanc. K et al. (2018) Best Practice recommendations for the prevention and management of skin tears in aged skin. Wounds International. [12] World Union of Wound Healing Societies (WUWHS) consensus document (2019) Wound exudate: effective assessment and management. Wounds International. *DT May 2020. Atrauman® Silicone 5 x 7cm, £1.13 per dressing. Mepitel® 5 x 7cm, £1.41 per dressing. Mepitel® is a registered trademark of Molnlycke